SGLT2 inhibitors

Acute coronary syndrome

Chronic coronary syndrome

Arrhythmias

Cardiomyopathies

Valvular heart disease

Chronic kidney disease

Acute myocardial infarction

Adenosine monophosphate-activated protein kinase

Brain-derived neurotrophic factor

Coronary artery disease

Calcium/calmodulin-dependent protein kinase II

Chronic kidney disease

Central nervous system

Cancer therapy-related cardiac dysfunction

Delayed after depolarization

Dilated cardiomyopathy

Estimated glomerular filtration rate

Extra-valvular cardiac damage

Extracellular vesicles

Fluorescent in situ hybridization

Guideline-directed medical therapy

Glucagon-like peptide 1

Glycogen synthase kinase-3 β

Hypertrophic cardiomyopathy

Hypoxia-inducible factor-1α/Vascular endothelial growth factor

Heart failure with preserved ejection fraction

Heart failure with reduced ejection fraction

Ischemic heart disease

Long QT syndrome type 3

Left ventricular ejection fraction

Mitral valve transcatheter edge-to-edge repair

Nuclear factor-kappa B

Sodium/hydrogen exchanger

Percutaneous coronary intervention

Programmed death-ligand 1

Phosphoinositide 3-kinase / Protein kinase B

Renin-angiotensin-aldosterone system

Randomized clinical trial

Reactive oxygen species

Ryanodine receptors 2

Sodium-glucose co-transporter 2

Superoxide dismutase 2

Signal transducer and activator of transcription 3

Type 2 diabetes mellitus

Transcatheter aortic valve implantation

Transforming growth factor-beta

Ventricular arrhythmias